STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

CorMedix Inc. to Participate in the RBC Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has announced its participation in the upcoming RBC Capital Markets Global Healthcare Conference. The event will be held in New York from May 20-21, 2025. The company will engage in a fireside chat format presentation scheduled for Wednesday, May 21, 2025, at 3:05 p.m. EDT. A webcast link will be available for interested parties to follow the presentation.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

+0.60% News Effect

On the day this news was published, CRMD gained 0.60%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BERKELEY HEIGHTS, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the RBC Capital Markets Global Healthcare Conference, taking place in New York on May 20-21, 2025.

RBC Capital Markets Global Healthcare Conference
Date:Wednesday, May 21, 2025
Time:3:05p.m. EDT
Format:Fireside Chat
Webcast:Link
  

About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas. For more information visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576


FAQ

When is CorMedix (CRMD) presenting at the RBC Global Healthcare Conference 2025?

CorMedix (CRMD) will present at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, at 3:05 p.m. EDT in a fireside chat format.

What type of company is CorMedix (CRMD)?

CorMedix (CRMD) is a biopharmaceutical company that focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions.

Where is the RBC Global Healthcare Conference 2025 being held?

The RBC Global Healthcare Conference 2025 is being held in New York on May 20-21, 2025.

How can I watch the CorMedix (CRMD) presentation at the RBC Healthcare Conference?

The presentation will be available via webcast, with a link provided for access.
Cormedix

NASDAQ:CRMD

CRMD Rankings

CRMD Latest News

CRMD Latest SEC Filings

CRMD Stock Data

924.98M
73.24M
7.56%
46.8%
15.92%
Biotechnology
Pharmaceutical Preparations
Link
United States
BERKELEY HEIGHTS